Search

Displaying results 3741 - 3750 of 9694 in total
  1. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge.

  2. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    Bromelain itself belongs to a category of protein-digesting enzymes that are obtained commercially from the fruit or stem of pineapples [A27198]. … Bromelain is consequently a composite mixture of several different endopeptidases that can facilitate many different reactions with many different substrates.

  3. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.

  4. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis. … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

  5. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively … [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.

  6. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells.

  7. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

    Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction … Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab].

  9. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351] It is effective against a wide range of Gram-positive and Gram-negative bacteria. … Polihexanide, also known as polyhexamethylene biguanide (PHMB), is a broad-spectrum antimicrobial polymer primarily used for topical antisepsis and wound management.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) [A32576]. … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].

    Products: PROPIVERIN AL 5MG, PROPIVERIN AL 15MG